3 Promising ASX Penny Stocks With Over A$80M Market Cap
Uncategorized
3 Promising ASX Penny Stocks With Over A$80M Market Cap
08 mins
The Australian share market is poised for a modest gain despite recent global volatility, highlighting the resilience of traders amidst ongoing geopolitical tensions and economic uncertainty. In such a climate, investors often seek out opportunities that balance affordability with growth potential, which is where penny stocks come into play. Although the term “penny stocks” might seem outdated, these smaller or newer companies can offer significant value when they possess strong financials and clear growth trajectories.
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Caravel Minerals Limited, with a market cap of A$184.39 million, explores for mineral tenements in Western Australia through its subsidiaries.
Operations: The company has not reported any revenue segments.
Market Cap: A$184.39M
Caravel Minerals, with a market cap of A$184.39 million, is pre-revenue and primarily focused on mineral exploration in Western Australia. The company has seen its debt to equity ratio increase significantly over the past five years, yet maintains a satisfactory net debt to equity ratio of 14%. Despite being unprofitable, Caravel has reduced its losses by 4.4% annually over the last five years and possesses sufficient cash runway for more than a year based on current free cash flow. Its management team and board are experienced, with average tenures of 6.5 and 6.8 years respectively.
ASX:CVV Debt to Equity History and Analysis as at Apr 2026
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Cynata Therapeutics Limited, with a market cap of A$85.48 million, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
Operations: The company’s revenue is derived from the development and commercialisation of therapeutic products, amounting to A$1.69 million.
Market Cap: A$85.48M
Cynata Therapeutics, with a market cap of A$85.48 million, operates in the biotech sector and is currently pre-revenue with earnings results showing a net loss reduction from A$3.65 million to A$2.66 million year-over-year. The company remains debt-free and has not diluted shareholders significantly over the past year, though it faces challenges with a negative return on equity of -248.04% due to unprofitability. Its short-term assets cover liabilities, but it has less than one year of cash runway based on free cash flow trends, indicating financial constraints amid its ongoing development efforts.
ASX:CYP Debt to Equity History and Analysis as at Apr 2026
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Delta Lithium Limited focuses on exploring and developing lithium properties in Western Australia, with a market capitalization of A$175.75 million.
Operations: Delta Lithium Limited has not reported any revenue segments.
Market Cap: A$175.75M
Delta Lithium Limited, with a market cap of A$175.75 million, operates in the lithium exploration sector and recently reported half-year revenue of A$1.32 million, showing minimal growth from the previous year. Despite being debt-free and having sufficient cash runway for over a year, the company remains pre-revenue with no significant earnings forecasted in the near future. While its short-term assets surpass liabilities significantly, Delta Lithium’s negative return on equity highlights ongoing unprofitability challenges. The company has not diluted shareholders recently but faces declining earnings projections over the next three years amidst industry volatility.
ASX:DLI Debt to Equity History and Analysis as at Apr 2026
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:CVV ASX:CYP and ASX:DLI.
This article was originally published by Simply Wall St.
